Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Colgate Palmolive (India) - 1QFY17 Result Update - Volumes Recover but at a Cost - Reliance Securities

Posted On: 2016-08-15 20:08:53

Net sales of Colgate Palmolive (India) grew 8.9% yoy to Rs10.1bn, while EBITDA growth was recorded at 3.6% and PBT (before exceptional items) increased by just 1.7% to Rs1.9bn in the quarter ended June 30, 2016. It reported overall volume growth of 6% with domestic volume growing by 5%. While gross sales growth was higher at 12.5%, net sales grew just 8.9% on account of sharp 49% jump in tax outgo resulting from phasing out of Excise Duties benefits.

Going forward, we estimate the volume growth to pick up pace, especially with the launch of Cibaca Vedshakti in the naturals space at an attractive price point. However, this is likely to keep A&P spends at elevated levels, which would drag earnings growth, in our view. We expect the Company to report 12.7% and 10% CAGR in revenues and earnings through FY16-18E. We reiterate our HOLD recommendation on the stock with revised Target Price of Rs1,055.

Volumes Recovery in Process

Domestic business witnessed 5% volume growth during the quarter. Although, the Company has lost market share on yoy basis, it has recovered some share sequentially. Volume-wise, market share in toothpaste stood at 55.9% in June'16 vs. 55.3% in Mar'16 and 57.9% in 1HCY15. On the other hand, volume market share in Toothbrush was higher both on yoy as well as qoq basis. It stood at 46.8% in June'16 vs. 45.8% in Mar'16 and 42.7% in 1HCY15. The Company stated that new products such as Colgate Sensitive Clove & Colgate A1 Toothbrush led overall growth in the quarter.

Higher A&P Spend Drags EBITDA Margins

Weak demand environment and heightened competitive intensity resulted in 190bps rise in A&P spends to 15.5% of sales. With launch of Cibaca Vedshakti at 30% discount to effectively counter Patanjali Dant Kanti, we expect A&P spends to remain at elevated levels, going forward. Although gross margins were higher by 140bps, higher A&P and staff cost dragged EBITDA margins by 100bps to 20.3% during the quarter.

Outlook & Valuation

We expect Colgate to post revenues of Rs46.4bn & Rs52.4bn and net profit of Rs6.4bn & Rs7.3bn in FY17E & FY18E respectively. Based on expected EPS of Rs27, currently the stock trades at 37.7x FY18E earnings. While we expect volume growth and market shares to recover, higher A&P spends could cap earnings growth in coming quarters. We retain our HOLD rating on the stock with revised Target Price of Rs1,055, based on 38x June'16 earnings, which is a 10% discount to its average one-year forward multiple.

Shares of COLGATE-PALMOLIVE (INDIA) LTD. was last trading in BSE at Rs.956 as compared to the previous close of Rs. 960.95. The total number of shares traded during the day was 21150 in over 918 trades.

The stock hit an intraday high of Rs. 970.5 and intraday low of 951. The net turnover during the day was Rs. 20342655.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Views on LIC Housing Finance Limited 4QFY2017 Results: Angel Broking
Wipro - Q4FY17 Result Review - Kotak Securities Limited
Views on Wipro Limited 4QFY2017 Results: Angel Broking
Axis Bank - Q4FY17 - Worst for the bank could get over in near term, better days ahead: Angel Broking
Ultratech Cement - Q4FY17 Result Review - Kotak Securities Limited
HDFC Bank back on growth trajectory: Angel Broking
Sun Pharmaceutical US Update: Angel Broking
Global ambiguity sizzles; Base metals' rally fizzles: Angel Broking
Asset quality a negative surprise form Yes Bank: Angel Broking
Heavy weight banks look a good bet: Angel Broking
Banks: Tightening the screws - Kotak
Utilities: The supply glut - Kotak
Insurance: Ending a strong year on a stronger note - Kotak
TCS - Q4FY17 result review - Kotak
Views on Tata Consultancy Services Limited 4QFY2017 Results: Angel Broking
Strategy: Small need not be beautiful - Kotak
Indiabulls Real Estate restructures to create value: Angel Broking
Infosys Q4 2017 results - Dipen Shah, Sr. Vice President - PCG Research, Kotak Securities Limited
Views on Infosys Ltd 4QFY2017 Results: Angel Broking
Infosys - 4QFY2017 Result Preview: Angel Broking
Metals & Mining (Attractive): 4QFY17 preview-when it shines the most - Kotak
Energy: Weaker end to a subdued year - Kotak
Apex court disallows rise in imported coal tariff, though awards compensation for lack of domestic coal
Utilities: Supreme Court-denies compensation, but with a rider - Kotak
Strategy: The curious case of the Indian market - Kotak Institutional Equities
Economy: INR: Appreciate, for now, but be cautious - Kotak Institutional Equities
Energy: OMCs Refining - marketing - Kotak Institutional Equities
Cement: Earnings weakness persists - Kotak Institutional Equities
Fall in IT conglomerates evened out by Banking counters: Angel Broking
Shankara Building Products lists at a healthy premium to issue price: Angel Broking
USFDA action on Indoco Plants: Angel Broking
Karur Vysya Bank - Easing troubles to pave way for growth: Angel Broking
Navin Fluorine International - The unique chemistry of growth: Angel Broking
Dr Reddy's inks distribution pact with Integra Life Sciences: Angel Broking
BS-IV rollout expected be neutral on the automobile sector: Angel Broking
Shankara Building Products Ltd - IPO Note - Sushil Finance
'R' for RERA - for Realty coming to Reality soon: Angel Broking
Reliance Capital - Refurbishing core; monetisation crucial; company update; Buy - Edelweiss
D-Mart delights its investors: Angel Broking
Shankara Building Products Limited - Thrust on retail to boost potential: Angel Broking
Impact of Rupee Strength on IT and Pharma: Angel Broking
Idea Surges 12% on the back of positive news flows: Angel Broking
Sun Pharmaceutical - USFDA to Lift Import Alert Regulator to permit supply of products from Mohali: Angel Broking
IT Update - Ban on premium processing of H1-B visas: Angel Broking
Tech Mahindra - Acquires CJS Solutions in US: Angel Broking
Dr. Reddy's Laboratories - Gets USFDA observation for Duvvada oncology formulation Facility: Angel Broking
VIP Industries - Travelling smart on the luggage track: Angel Broking
Avenue Supermarts - IPO Note - Numero Uno! - Reliance Securities
IT Update: Ban on premium processing of H1-B visas: Angel Broking
DATA WARS BEGIN... AND THE WINNER IS: THE DATA CONSUMER: Angel Broking


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017